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Human herpesvirus 6 (HHV-6), a common resident virus
of the human central nervous system (CNS), has been
implicated in both acute and chronic inflammatory-
demyelinating diseases. HHV-6 persists within the human
CNS and has been described to infect mature oli-
godendrocytes and astrocytes. We recently demonstrated
that HHV-6 infects human glial precursor cells, the ances-
tors of myelin producing oligodendrocytes, in vitro. Pro-
ductive infection was demonstrated by both electron
microscopy and expression of viral gene transcripts and
proteins. Infection led to impairment of cell replication
but not increased cell death. Infected cells showed
decreased proliferation as measured by BrdU uptake and
demonstrated strong G1/S-phase inhibition by FACS. We
now present evidence detailing both specific viral and cell
cycle genes inducing cellular G1/S cell cycle arrest. In par-
allel with human cells, the well characterized rodent oli-
godendroglial progenitor cell (OPC) system was used.
Restricted infection of the murine cells was demonstrated
by quantitative PCR, EM, and RT-PCR, and IFA for viral
late proteins but, intriguingly, reproduced the G1/S arrest
seen after productive virus infection of human progeni-
tors. Restricted infection of murine OPCs was also found
to be sufficient to induce the activation of DNA damage
pathways previously reported by our group in human glial
progenitors (ISNV 2004) and after productive infection in
human lymphocytes (Oster et al. 2005). IFA and immu-
noblot again demonstrated expression of phospho-ATM,
CHK-2, and p53 in infected murine precursors and two
viral IE proteins were sufficient to induce G1/S arrest.
Virus-induced cell-cycle arrest was accompanied by GalC+
differentiation with corresponding loss of the OPC pool
as had been previously seen in the human precursors.
Enhanced GFP-expressing murine OPCs have been cre-
ated that can be readily infected with ALEXA-632-labeled
HHV-6, allowing both sorting for infected cells and their
identification in evaluating repair in demyelinated mice.
In light of recent observations that repair of CNS remyeli-
nation is dependent on the generation of mature oli-
godendrocytes from the glial precursor cell pool, these
findings may have broad implications for both the inef-
fective repair seen in human demyelinating diseases and
the disruption of normal glial differentiation.
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